Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study

医学 重症肌无力 耐受性 不利影响 抗原 嵌合抗原受体 自身抗体 免疫疗法 内科学 胃肠病学 免疫学 抗体 癌症
作者
Volkan Granit,Michael Benatar,Metin Kurtoğlu,Miloš D Miljković,Nizar Chahin,Gregory Sahagian,Marc H Feinberg,Adam Slansky,Tuan Vu,Christopher M. Jewell,Michael S. Singer,Murat V. Kalayoglu,James F. Howard,Tahseen Mozaffar,Volkan Granit,Michael Benatar,Tahseen Mozaffar,Nizar Chahin,James F. Howard,Adam D Slansky,Marc H Feinberg,Gregory Sahagian,Tuan Vu,Denise Pereira,Julie Steele,Marcelo Paredes,Cara L. Benjamin,Krishna V. Komanduri,Thomas H. Brannagan,Jerry J. Fong,Luis de la Cruz,Diana Dimitrova,Manisha Chopra,Keith E. Holley,Gabrielle DeMaria,Antonio Tenorio,Naraly Requena,Benjamin Brooks,Niraja Suresh,Jerrica Farias,Miloš D Miljković,Metin Kurtoğlu,M. Casi,Abhijit Chowdhury,Hafsa Kamboh,Charles A. Stewart,Mehmet Tosun,Yufei Shan,S. E. Daniel,Matthew T. Duvernay,Maria L. Kireeva,Emily English,Christopher M. Jewell,Michael S. Singer,Murat V. Kalayoglu
出处
期刊:Lancet Neurology [Elsevier]
卷期号:22 (7): 578-590 被引量:37
标识
DOI:10.1016/s1474-4422(23)00194-1
摘要

Summary

Background

Chimeric antigen receptor (CAR) T cells are highly effective in treating haematological malignancies, but associated toxicities and the need for lymphodepletion limit their use in people with autoimmune disease. To explore the use of CAR T cells for the treatment of people with autoimmune disease, and to improve their safety, we engineered them with RNA (rCAR-T)—rather than the conventional DNA approach—to target B-cell maturation antigen (BCMA) expressed on plasma cells. To test the suitability of our approach, we used rCAR-T to treat individuals with myasthenia gravis, a prototypical autoantibody disease mediated partly by pathogenic plasma cells.

Methods

MG-001 was a prospective, multicentre, open-label, phase 1b/2a study of Descartes-08, an autologous anti-BCMA rCAR-T therapy, in adults (ie, aged ≥18 years) with generalised myasthenia gravis and a Myasthenia Gravis Activities of Daily Living (MG-ADL) score of 6 or higher. The study was done at eight sites (ie, academic medical centres or community neurology clinics) in the USA. Lymphodepletion chemotherapy was not used. In part 1 (phase 1b), participants with Myasthenia Gravis Foundation of America (MGFA) disease class III–IV generalised myasthenia gravis received three ascending doses of Descartes-08 to determine a maximum tolerated dose. In part 2 (phase 2a), participants with generalised myasthenia gravis with MGFA disease class II–IV received six doses at the maximum tolerated dose in an outpatient setting. The primary objective was to establish safety and tolerability of Descartes-08; secondary objectives were to assess myasthenia gravis disease severity and biomarkers in participants who received Descartes-08. This trial is registered with clinicaltrials.gov, NCT04146051.

Findings

We recruited 16 individuals for screening between Jan 7, 2020 and Aug 3, 2022. 14 participants were enrolled (n=3 in part 1, n=11 in part 2). Ten participants were women and four were men. Two individuals did not qualify due to low baseline MG-ADL score (n=1) or lack of generalised disease (n=1). Median follow-up in part 2 was 5 months (range 3–9 months). There was no dose-limiting toxicity, cytokine release syndrome, or neurotoxicity. Common adverse events were headache (six of 14 participants), nausea (five of 14), vomiting (three of 14), and fever (four of 14), which resolved within 24 h of infusion. Fevers were not associated with increased markers of cytokine release syndrome (IL-6, IL-2, and TNF). Mean improvements from baseline to week 12 were –6 (95% CI –9 to –3) for MG-ADL score, –7 (–11 to –3) for Quantitative Myasthenia Gravis score, –14 (–19 to –9) for Myasthenia Gravis Composite score, and –9 (–15 to –3) for Myasthenia Gravis Quality of Life 15-revised score.

Interpretation

In this first study of an rCAR-T therapy in individuals with an autoimmune disease, Descartes-08 appeared to be safe and was well tolerated. Descartes-08 infusions were followed by clinically meaningful decreases on myasthenia gravis severity scales at up to 9 months of follow-up. rCAR-T therapy warrants further investigation as a potential new treatment approach for individuals with myasthenia gravis and other autoimmune diseases.

Funding

Cartesian Therapeutics and National Institute of Neurological Disorders and Stroke of the National Institutes of Health.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
宋行远发布了新的文献求助10
3秒前
3秒前
qnmlgbd55发布了新的文献求助10
5秒前
ANGHUI完成签到,获得积分10
7秒前
枫叶发布了新的文献求助30
7秒前
在水一方应助晾猫人采纳,获得10
13秒前
深情安青应助晾猫人采纳,获得30
13秒前
可爱的函函应助晾猫人采纳,获得10
13秒前
烟花应助晾猫人采纳,获得30
13秒前
传奇3应助晾猫人采纳,获得10
13秒前
小二郎应助晾猫人采纳,获得10
13秒前
彭于晏应助晾猫人采纳,获得10
13秒前
18秒前
JamesPei应助qnmlgbd55采纳,获得10
20秒前
23秒前
小马甲应助受伤的便当采纳,获得10
24秒前
ad钙发布了新的文献求助10
24秒前
34秒前
Maestro_S应助枫叶采纳,获得10
34秒前
34秒前
可可发布了新的文献求助10
36秒前
37秒前
疯度发布了新的文献求助10
39秒前
42秒前
kunyi发布了新的文献求助30
44秒前
44秒前
小小aa16完成签到,获得积分10
44秒前
wxt完成签到 ,获得积分10
45秒前
46秒前
疯度完成签到,获得积分20
46秒前
47秒前
47秒前
qnmlgbd55发布了新的文献求助10
48秒前
Xi ~发布了新的文献求助10
48秒前
南风发布了新的文献求助10
50秒前
qiu发布了新的文献求助20
52秒前
52秒前
XP416完成签到,获得积分10
53秒前
53秒前
Xi ~完成签到,获得积分10
55秒前
高分求助中
Teaching Social and Emotional Learning in Physical Education 900
Plesiosaur extinction cycles; events that mark the beginning, middle and end of the Cretaceous 800
Recherches Ethnographiques sue les Yao dans la Chine du Sud 500
Two-sample Mendelian randomization analysis reveals causal relationships between blood lipids and venous thromboembolism 500
Chinese-English Translation Lexicon Version 3.0 500
[Lambert-Eaton syndrome without calcium channel autoantibodies] 440
Wisdom, Gods and Literature Studies in Assyriology in Honour of W. G. Lambert 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2389769
求助须知:如何正确求助?哪些是违规求助? 2095772
关于积分的说明 5278818
捐赠科研通 1822898
什么是DOI,文献DOI怎么找? 909318
版权声明 559593
科研通“疑难数据库(出版商)”最低求助积分说明 485920